TY - JOUR
T1 - Usefulness of Atherectomy in Chronic Total Occlusion Interventions (from the PROGRESS-CTO Registry)
AU - Xenogiannis, Iosif
AU - Karmpaliotis, Dimitri
AU - Alaswad, Khaldoon
AU - Jaffer, Farouc A.
AU - Yeh, Robert W.
AU - Patel, Mitul
AU - Mahmud, Ehtisham
AU - Choi, James W.
AU - Burke, M. Nicholas
AU - Doing, Anthony H.
AU - Dattilo, Phil
AU - Toma, Catalin
AU - Smith, A. J.Conrad
AU - Uretsky, Barry
AU - Krestyaninov, Oleg
AU - Khelimskii, Dmitrii
AU - Holper, Elizabeth
AU - Potluri, Srinivas
AU - Wyman, R. Michael
AU - Kandzari, David E.
AU - Garcia, Santiago
AU - Koutouzis, Michalis
AU - Tsiafoutis, Ioannis
AU - Khatri, Jaikirshan J.
AU - Jaber, Wissam
AU - Samady, Habib
AU - Jefferson, Brian K.
AU - Patel, Taral
AU - Moses, Jeffrey W.
AU - Lembo, Nicholas J.
AU - Parikh, Manish
AU - Kirtane, Ajay J.
AU - Ali, Ziad A.
AU - Doshi, Darshan
AU - Tajti, Peter
AU - Rangan, Bavana V.
AU - Abdullah, Shuaib
AU - Banerjee, Subhash
AU - Brilakis, Emmanouil S.
N1 - Funding Information:
Dr. Kandzari: research grant: Boston Scientific and Medtronic Cardiovascular, Abbott. Consultant/Advisory Board: Boston Scientific and Medtronic Cardiovascular.
Funding Information:
Dr. Rangan: research grants from InfraReDx, Inc., and The Spectranetics Corporation.
Funding Information:
Dr. Khatri: research grant support: Asahi Intecc. Speaker/Proctor: Abbott Vascular
Funding Information:
Funding Sources: The Progress CTO registry has received support from the Abbott Northwestern Hospital Foundation , Minneapolis, MN.
Funding Information:
Dr. Banerjee: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel.
Funding Information:
Dr. Ali: consultant fees/honoraria from St. Jude Medical, and AstraZeneca Pharmaceuticals; ownership interest/partnership/principal in Shockwave Medical and VitaBx Inc; and research grants from Medtronic and St. Jude Medical.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - There is limited data on the use of atherectomy during chronic total occlusion (CTO) percutaneous coronary intervention (PCI). We compared the clinical and procedural characteristics and outcomes of CTO PCIs performed with or without atherectomy in a contemporary multicenter CTO PCI registry. Between 2012 and 2018, 3,607 CTO PCIs were performed at 21 participating centers. Atherectomy was used in 117 (3.2%) cases: rotational atherectomy in 105 cases, orbital atherectomy in 8, and both in 4 cases. Patients in whom atherectomy was used, were older (68 ± 8 vs 64 ± 10 years, p <0.0001) and had higher Japan-chronic total occlusion score (3.0 ± 1.2 vs 2.4 ± 1.3, p <0.0001). CTO PCI cases in which atherectomy was used had similar technical (91% vs 87%, p = 0.240) and procedural (90% vs 85%, p = 0.159) success and in-hospital major adverse cardiac event (4% vs 3%, p = 0.382) rates. However, atherectomy cases were associated with higher rates of donor vessel injury (4% vs 1%, p = 0.031), tamponade requiring pericardiocentesis (2.6% vs 0.4%, p = 0.012) and more often required use of a left ventricular assist device (9% vs 5%, p = 0.031). Atherectomy cases were associated with longer procedural duration (196 [141, 247] vs 119 [76, 180] minutes, p <0.0001), and higher patient air kerma radiation dose (3.6 [2.5, 5.6] vs 2.8 [1.6, 4.7] Gray, p = 0.001). In conclusion, atherectomy is currently performed in approximately 3% of CTO PCI cases and is associated with similar technical and procedural success and overall major adverse cardiac event rates, but higher risk for donor vessel injury and tamponade.
AB - There is limited data on the use of atherectomy during chronic total occlusion (CTO) percutaneous coronary intervention (PCI). We compared the clinical and procedural characteristics and outcomes of CTO PCIs performed with or without atherectomy in a contemporary multicenter CTO PCI registry. Between 2012 and 2018, 3,607 CTO PCIs were performed at 21 participating centers. Atherectomy was used in 117 (3.2%) cases: rotational atherectomy in 105 cases, orbital atherectomy in 8, and both in 4 cases. Patients in whom atherectomy was used, were older (68 ± 8 vs 64 ± 10 years, p <0.0001) and had higher Japan-chronic total occlusion score (3.0 ± 1.2 vs 2.4 ± 1.3, p <0.0001). CTO PCI cases in which atherectomy was used had similar technical (91% vs 87%, p = 0.240) and procedural (90% vs 85%, p = 0.159) success and in-hospital major adverse cardiac event (4% vs 3%, p = 0.382) rates. However, atherectomy cases were associated with higher rates of donor vessel injury (4% vs 1%, p = 0.031), tamponade requiring pericardiocentesis (2.6% vs 0.4%, p = 0.012) and more often required use of a left ventricular assist device (9% vs 5%, p = 0.031). Atherectomy cases were associated with longer procedural duration (196 [141, 247] vs 119 [76, 180] minutes, p <0.0001), and higher patient air kerma radiation dose (3.6 [2.5, 5.6] vs 2.8 [1.6, 4.7] Gray, p = 0.001). In conclusion, atherectomy is currently performed in approximately 3% of CTO PCI cases and is associated with similar technical and procedural success and overall major adverse cardiac event rates, but higher risk for donor vessel injury and tamponade.
UR - http://www.scopus.com/inward/record.url?scp=85061772797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061772797&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2019.01.054
DO - 10.1016/j.amjcard.2019.01.054
M3 - Article
C2 - 30798947
AN - SCOPUS:85061772797
SN - 0002-9149
VL - 123
SP - 1422
EP - 1428
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 9
ER -